Muir-Torre syndrome associated with alpha 1-antitrypsin deficiency and cutaneous vasculitis. Report of a case with exacerbation of a cutaneous neoplasm during immunosuppressive therapy.
We describe a patient with both Muir-Torre syndrome and alpha 1-antitrypsin deficiency. A keratoacanthoma developed after immunosuppressive therapy for necrotizing vasculitis. To our knowledge, this is the first reported case of Muir-Torre syndrome associated with alpha 1-antitrypsin deficiency.
Guitart
J
J
Department of Dermatology, Cleveland Clinic Foundation, Ohio.
McGillis
S T
ST
Bergfeld
W F
WF
Tuthill
R J
RJ
Bailin
P L
PL
Camisa
C
C
D000230:Adenocarcinoma / Q000473:pathology*; D000236:Adenoma / Q000473:pathology; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005145:Face; D005153:Facial Neoplasms / Q000473:pathology; D006801:Humans; D007636:Keratoacanthoma / Q000473:pathology*; D008297:Male; D009361:Neoplasm Invasiveness; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D012626:Sebaceous Gland Neoplasms / Q000473:pathology; D012811:Sigmoid Neoplasms / Q000473:pathology*; D012867:Skin / Q000098:blood supply*; D012871:Skin Diseases / Q000473:pathology*; D013577:Syndrome; D014657:Vasculitis / Q000188:drug therapy / Q000473:pathology*; D019896:alpha 1-Antitrypsin Deficiency
D003520:Cyclophosphamide